Thallium-201 imaging in the assessment of tumor response to anti-tumor treatments

Q J Nucl Med. 2003 Mar;47(1):63-74.

Abstract

The advantages and limitations of (201)Tl imaging in assessing the tumor response to anti-cancer therapy are discussed in this review. (201)Tl has distinctive advantages but more recent agents such as (99m)Tc MIBI and positron emitters have some clinical superiorities over (201)Tl in this usage.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / therapy
  • Head and Neck Neoplasms / diagnostic imaging
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / radiotherapy
  • Head and Neck Neoplasms / therapy
  • Humans
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / radiotherapy
  • Lung Neoplasms / therapy
  • Neoplasms / diagnostic imaging*
  • Neoplasms / drug therapy
  • Neoplasms / radiotherapy
  • Neoplasms / therapy*
  • Prognosis
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Soft Tissue Neoplasms / diagnostic imaging
  • Soft Tissue Neoplasms / drug therapy
  • Soft Tissue Neoplasms / radiotherapy
  • Soft Tissue Neoplasms / therapy
  • Thallium*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Radiopharmaceuticals
  • thallium chloride
  • Thallium